US 12,213,913 B2
Medical implant
Thomas A. Shepard, Rolesville, NC (US); Tyler Pegoraro, Raleigh, NC (US); Stuart Williams, Raleigh, NC (US); Sanjib Kumar Das, Cary, NC (US); Leo Anthony Trevino, Hurdle Mills, NC (US); and Cheng Li, Durham, NC (US)
Assigned to ALCON INC., Fribourg (CH)
Filed by ALCON INC., Fribourg (CH)
Filed on Aug. 23, 2022, as Appl. No. 17/893,338.
Application 17/893,338 is a continuation of application No. 17/518,281, filed on Nov. 3, 2021.
Claims priority of provisional application 63/241,395, filed on Sep. 7, 2021.
Claims priority of provisional application 63/109,615, filed on Nov. 4, 2020.
Prior Publication US 2024/0065970 A1, Feb. 29, 2024
Int. Cl. A61F 9/00 (2006.01); A61K 9/00 (2006.01); B29C 33/38 (2006.01); G03F 7/00 (2006.01)
CPC A61F 9/0017 (2013.01) [A61K 9/0024 (2013.01); A61K 9/0051 (2013.01); B29C 33/3842 (2013.01); G03F 7/0002 (2013.01); B29K 2867/003 (2013.01); B29K 2883/00 (2013.01)] 16 Claims
OG exemplary drawing
 
1. A layered composite containing a drug comprising: a substantially wedge shaped body having a width and a height; a tapered portion extending in a width direction between a first end and a second end, wherein the first end is configured to be initially retained in a cannula and the second end is configured to be inserted into an eye, wherein the first end has a first cross-section having a first cross-sectional dimension in a width direction and the second end has a second cross-section having a second cross-sectional dimension in the width direction, the first cross-sectional dimension being larger than the second cross-sectional dimension, wherein the tapered portion has a rectangular cross-section in the width direction, and wherein the height is substantially constant between the first end and the second end; a first layer comprising a first polymer; and a second layer comprising a first drug and a second polymer; wherein the first layer substantially covers the second layer and where a portion of the first layer defines a flat planar surface; wherein a retention force of the implant within the cannula is from about 0.030 N to about 0.260 N; and wherein a ratio of a diagonal dimension of the first cross-section, as a measured retention dimension, to an inside diameter of the cannula is between 1.0064 and 1.09 such that the body is configured to be inserted and removed from the cannula by a user for insertion of the body into an eye of a patient for medical treatment of the eye.